Skye Bioscience is advancing nimacimab, a novel antibody designed to selectively inhibit peripheral CB1 receptors implicated in metabolic dysfunction without CNS side effects. The company’s financials reflect substantial operating losses and cash burn typical of clinical-stage biotechs without product revenue, raising liquidity concerns. Recent positive Phase 2a trial data support nimacimab’s potential, but ongoing risks include regulatory hurdles and material litigation. Near-term success depends on clinical progress, capital raises, and managing legal exposures.